Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by stockfyon Jan 24, 2021 4:55am
301 Views
Post# 32370088

CPH repurchased at C$1.14 and Employees bought at C$1.05

CPH repurchased at C$1.14 and Employees bought at C$1.05
In August 2020, debt-free and profitable CPH announced that the TSX had approved the company’s Notice of Intention to make a Normal Course Issuer Bid. So during the period ended September 30, 2020, CPH repurchased 30,000 shares at an average price of C$1.14, facts below: 
 
"During the period ended September 30, 2020, the Company purchased for cancellation 30,000 common shares at an average price of C$1.14 per common share."
 
And the company's CEO also stated recently in the latest CC that the company will buy back as much stock as it can: 
 
"Craig Mull: Well, Peter, we were under a blackout for a good part of that. We are restricted from buying. I can tell you what our intentions are going forward. We expect to be an active buyer of our stock, subject to the regulatory requirements that we have to abide by. So we had an active – the stock is as you no doubt can see it’s very thinly traded. We would like to buy as much stock as we can." 

 
Additionally, under the company's ESPP program, the employees bought 46,084 shares at an average price of C$1.05 in the first nine months of 2020, facts below:
 
"During the three months ended September 30, 2020, 13,077 shares were issued under the ESPP at weighted average trading price of C$1.27.
 
During the nine months ended September 30, 2020, 46,084 shares were issued under the ESPP at weighted average trading price of C$1.05."


 
<< Previous
Bullboard Posts
Next >>